DiscoverEagle's Eye View: Your Weekly CV Update From ACC.orgCarvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension
Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension

Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension

Update: 2025-05-28
Share

Description

In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension. 

 
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension

Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension